We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ERDRP-0519 inhibits feline coronavirus in vitro.
- Authors
Camero, Michele; Lanave, Gianvito; Catella, Cristiana; Lucente, Maria Stella; Sposato, Alessio; Mari, Viviana; Tempesta, Maria; Martella, Vito; Buonavoglia, Alessio
- Abstract
Background: Coronaviruses (CoVs) are major human and animal pathogens and antiviral drugs are pursued as a complementary strategy, chiefly if vaccines are not available. Feline infectious peritonitis (FIP) is a fatal systemic disease of felids caused by FIP virus (FIPV), a virulent pathotype of feline enteric coronavirus (FeCoV). Some antiviral drugs active on FIPV have been identified, but they are not available in veterinary medicine. ERDRP-0519 (ERDRP) is a non-nucleoside inhibitor, targeting viral RNA polymerase, effective against morbilliviruses in vitro and in vivo. Results: The antiviral efficacy of ERDRP against a type II FIPV was evaluated in vitro in Crandell Reese Feline Kidney (CRFK) cells. ERDRP significantly inhibited replication of FIPV in a dose-dependent manner. Viral infectivity was decreased by up to 3.00 logarithms in cell cultures whilst viral load, estimated by quantification of nucleic acids, was reduced by nearly 3.11 logaritms. Conclusions: These findings confirm that ERDRP is highly effective against a CoV. Experiments will be necessary to assess whether ERDRP is suitable for treatment of FIPV in vivo.
- Subjects
CORONAVIRUSES; VETERINARY medicine; ANTIVIRAL agents; VIRAL load; NUCLEIC acids; RNA polymerases
- Publication
BMC Veterinary Research, 2022, Vol 18, Issue 1, p1
- ISSN
1746-6148
- Publication type
Article
- DOI
10.1186/s12917-022-03153-3